Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica

View original at globenewswire.com
Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asia-Pacific is projected to witness the fastest CAGR from 2025 to 2034

    80% confidence

  • A 160% increase in pancreatic cancer survival rates was reported in 2024 due to clinical trial advancements

    80% confidence

  • Global spending on cancer medicines reached USD 252 billion in 2024, reflecting a USD 29 billion increase from the previous year

    80% confidence

  • The number of oncology Novel Active Substances (NAS) launched globally in the 5-year period ending 2024 reached 132

    80% confidence

  • North America accounted for over 41.58% revenue share of the oncology clinical trials market

    80% confidence

  • Spending on cancer medicines will reach USD 441 billion by 2029

    80% confidence

  • The global oncology clinical trials market is projected to hit the market valuation of USD 25.61 billion by 2035 from USD 14.95 billion in 2025 at a CAGR of 5.53% during the forecast period 2026–2035

    80% confidence

  • 2,162 oncology clinical trials were initiated globally in 2024, representing a 12-unit increase on an index basis compared to 2019 levels

    80% confidence

  • The probability of technical success for ADC monotherapies in Phase III is 53%, higher than the general oncology average

    80% confidence

  • Biosimilars in oncology generated USD 7 billion in savings for payers in 2023/2024, with cumulative savings reaching USD 19 billion since 2017

    80% confidence

  • Novel modalities, including ADCs and Cell/Gene therapies, accounted for 35% of all oncology trial starts in 2024

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals17 drugs
U.S. Food and Drug Administration · approval decisions32 decisions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica — Source | Via News | ViaNews EU